Teprotumumab more Beneficial Than IV Methylprednisolone in Patients with Proptosis & Diplopia MD Bureau23 Feb 2022 9:00 AM ISTThyroid eye disease (TED) causes expansion of retro-orbital fat and extraocular muscle thought to be mediated primarily by the upregulation of the...
Reoperation risk high in Thyroid eye disease patients Dr. Nandita Mohan28 Dec 2021 2:48 PM ISTA new study shows that after strabismus surgery, approximately one of every four patients with thyroid eye disease (TED) requires reoperation. The...
Medical Bulletin 27/December/2021 Dr. Nandita Mohan27 Dec 2021 5:23 PM ISTHere are Top Medical stories of the dayGender Differences In Hypertension Control Widen With Advancing AgeCardiovascular disease is the leading cause...
Patients with thyroid eye disease at increased reoperation risk after strabismus surgery: Study MD Editorial Team22 Dec 2021 9:00 AM ISTCalifornia: A new study shows that after strabismus surgery, approximately one of every four patients with thyroid eye disease (TED) requires...
Teprotumumab effective in Thyroid Eye Disease but may take longer time to act in some: Study Dr. Shravani Dali15 Sept 2021 8:45 AM ISTTeprotumumab Early Response Is Not Required for Benefit for Thyroid Eye Disease, suggests a study published in the Eye (Lond). In recent trials,...
Teprotumumab use in thyroid eye disease tied to rapid progressive cognitive decline: Case report Dr Ishan Kataria25 May 2021 9:00 PM ISTTeprotumumab (Tepezza), an insulin-like growth factor type 1 receptor antagonist (IGF-1R), was approved for treatment of thyroid eye disease in...
Teprotumumab: Drug to reduce asymmetry in thyroid eye disease Dr Ishan Kataria12 May 2021 6:15 AM ISTTeprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid...
Increased risk of hearing impairment with new thyroid eye disease treatment Hina Zahid31 March 2021 5:15 AM ISTWASHINGTON - More patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for...
Teprotumumab shows promise in managing asymmetry linked to thyroid eye disease; BJO Dr Satabdi Saha17 March 2021 7:45 AM ISTTeprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye...
US FDA approves Tepezza- first treatment for thyroid eye disease MD Bureau22 Jan 2020 10:32 AM ISTUS : The U.S. Food and Drug Administration (FDA) has given its nod to Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye...
